中文
EN
ABOUT Viwit
With high-quality products and services, we continue to create more value for our customers, employees, shareholders and society, and contribute our talents and efforts to a healthier and better life
COMPANY PROFILE
Viwit is an innovation driven biopharmaceutical and healthcare company with integrated research and development, production and marketing systems. Viwit is committed to building a platform for pharmaceutical innovation and commercialization, and establishing an ecosystem that serves the healthcare needs of the general public.
Viwit was founded in 2006 as an R&D lab. With the collaborative efforts of the Viwit team, Viwit Pharmaceutical has evolved from developing chiral borane products to making drug intermediates, active pharmaceutical ingredients and biopharmaceutical products. Viwit has three integrated product research and development (R&D) centers, three cGMP production facilities (refer to history of Viwit), and marketing distribution systems in China, the United States, Canada, European Union and other regions. Viwit is continuously focusing and expanding its business scope and operations in the biopharmaceutical and healthcare industry.
PRODUCT INTRODUCTION
We are committed to developing into a global leading medical and health enterprise based on the overall competitive advantage of the industrial chain and based on technological innovation
Drug Products
Cardiovascular drugs
Anti-infective drugs
Anti-inflammatory analgesics
Anti-viral drugs
CNS medication
HIGH DEMAND PRODUCTS
Adhering to customer demand, building core competitiveness, and striving to provide better and higher quality health products and services
INNOVATION
& collaboration platform
CDMO
Viwit platform provides CDMO services of APIs and intermediates, oral solids (tablets, capsules), sterile liquid products (small volume injections-ampoules, vials, eye drops).
View More +
Project Collaboration
Viwit platform provides R&D project cooperation and commercialization, covering the entire pharma industrial value chain from finished drugs to APIs.
View More +
In-/Out-Licensing
Viwit is dedicated to developing and providing innovative, valuable drugs to the general public and assisting our business partners to bring high-quality products to global markets.
View More +
BLOG CENTER
Make due contribution to the development of the industry and society, and strive to become the pacesetter and pioneer of the industry.
2024
12-16
Recently, Viwit Pharmaceuticals received ‘Drug Registration Certificate’ issued by China National Medical Products Administration (NMPA) for independently developed Phenylephrine Hydrochloride Injection, the approval number is H20249727. This signifies that the product has received official approval for the Chinese market and been recognized as having passed the generic drug consistency evaluation.
2024
12-04
Recently, Viwit Pharmaceuticals received the "Drug registration certificate" issued by China National Medical Products Administration (NMPA) for Brimonidine Tartrate and Timolol Maleate Eye Drops. The approval number is H20249650. This signifies that the product has received official approval for the Chinese market and has successfully passed the generic drug consistency evaluation.
2024
10-22
Viwit's Nitroglycerin Sublingual Tablets Approved by FDA
Recently, Viwit Pharmaceuticals' proprietary developed Nitroglycerin Sublingual Tablets (strengths: 0.3 mg, 0.4 mg, 0.6 mg) received a marketing authorization letter from the US Food and Drug Administration (US FDA), ANDA number: 218583, signifying the product's official approval in the US market.
2024
09-23
Viwit Pharmaceuticals API Site Successfully Passed FDA cGMP On-site Audit with "No Action Indicated"
From July 15 to 19, 2024, FDA inspectors conducted a five-day on-site cGMP (Current Good Manufacturing Practice) inspection of Viwit Pharmaceuticals Co., Ltd. (referred to as Viwit API manufacturing facility). Recently, the FDA's official website showed that Viwit's API manufacturing facility successfully passed the cGMP on-site audit with a perfect result of NAI, meaning "Zero 483". This is the second time Viwit's API manufacturing facility has successfully passed the U.S. FDA audit, further affirming Viwit’s robust and continuous production management and quality systems.
2024
09-18
Viwit Pharmaceuticals (Viwit), an innovation driven biopharmaceutical and healthcare company has entered into an exclusive licensing and supply agreement with Zydus Lifesciences Ltd.’s wholly owned subsidiary, Zydus Lifesciences Global FZE for Gadobutrol Injection (generic version of GADAVIST) and Gadoterate Meglumine Injection (generic version of DOTAREM) for the US market.